Fig. 8

Drug combinations reduce tumor volume and luciferase signal in an NCI-H295R-Luc-cell-mediated xenograft model: A Schematic diagram showing treatment times, dosages, drug delivery routes and endpoint of the study. B Effects of OTS167, RGB-286638, and a combination of OTS167 and RGB-286638 in NCI-H295R-Luc mediated xenograft tumors in athymic nude mice. Luciferase level NCI-H295R cells were implanted in athymic nude mice. Bioluminescence images of NCI-H295R subcutaneous xenografts are shown. The upper row shows mice treated with vehicle control (Group 1); the middle two rows (Group 2 and 3) show mice treated with 10 mg/kg/BW OTS167 and 20 mg/kg/BW RGB-286638, respectively; and the bottom row (Group 4) shows mice treated with a combination of OTS167 and RGB-286638. C Weekly fold change of the luciferase signal of each group (Group 1, Group 2, Group 3, and Group 4). All data were analyzed by two-tailed unpaired one-way ANOVA. D Fold change of the luciferase signal of each group (Group 1, Group 2, Group 3, and Group 4) at the final day (week 5). E Caliper measurement of tumor volume at the final day (week 5) of treatment in different groups. Tumor sizes were unmeasurable due to the smaller size in one mouse from groups 1 and 3, two mice from group 2, and three mice from group 4. F Average weight of mice measured weekly from each group. G IHC study of β-catenin, vimentin, and cleaved caspase-3 from mouse tumor tissue. The bottom graph represents the percentage (%) of β-catenin, vimentin, and cleaved caspase-3 expression in Group 2 (OTS167 treatment), Group 3 (RGB-286638 treatment), and Group 4 (OTS167 and RGB-286638 combination treatment) with respect to Group 1 (vehicle treatment)